SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

NSPR

InspireMD Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5d ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor the pace of U.S. commercial launch of CGuard Prime for TCAR in Q4 2026 and early 2027 revenue trajectory. Also watch for the PMA supplement submission for CGuard Prime for CAS and the cash burn rate given the $19.2M cash position.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6441
T+0 close · Nov 12, 2026 · via day close
Latest settled
−6.85%
T+1 · $0.6000
Vs SPY
−4.94%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.6441entry
  2. T+1 · yesterday −6.85%α −4.94% · $0.6000
  3. T+2 · todayOpen
  4. T+5 · in 3d Pending
  5. T+20 · in 27d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InspireMD reported Q3 2026 revenue of $2.24M, below the $2.0M consensus, and a GAAP net loss of $0.12 per share, narrower than the consensus loss of $0.15. The headline is the FDA approval of CGuard Prime for TCAR procedures, which expands the U.S. addressable market by over 35,000 procedures annually and enables a U.S. commercial re-entry in Q4 2026. However, total revenue fell 11% YoY due to the voluntary recall of the CGuard Prime for CAS delivery system, and the company's cash position dropped to $19.2M from $54.2M at year-end 2025, raising liquidity concerns.

Key Financial Metrics

EPS
−$0.12
est −$0.15 · +20.0%
Revenue
$2.2M
est $2.0M · +12.1% · -11.1% YoY
Rating
beat
Gross Margin
10.7%

Key Facts

  • FDA approval of CGuard Prime for TCAR procedures, expanding U.S. addressable market by over 35,000 procedures annually
  • Q3 2026 total revenue $2.24M, down 11.1% YoY from $2.52M
  • Q3 2026 GAAP net loss $0.12 per share vs $0.17 loss in Q3 2025
  • International revenue $2.21M, up 9.1% YoY; U.S. revenue $32,000 vs $497,000 due to recall
  • Cash and marketable securities $19.2M at Sep 30, 2026, down from $54.2M at Dec 31, 2025
  • Restructuring expenses of $1.07M in Q3 2026
  • Company expects to submit PMA supplement for enhanced CGuard Prime for CAS in December 2026 with potential re-launch in H1 2027

Financial Impact

FDA approval of CGuard Prime for TCAR opens a U.S. market opportunity of over 35,000 procedures annually, potentially doubling the addressable market. Q3 revenue missed consensus by $0.24M, but the net loss was narrower than expected.

revenuenet losscashaddressable market

Segment Breakdown

SegmentRevenueGrowth
International$2.2M+9.1%
U.S.$32.0K-93.6%

Risk Factors

  • Cash burn continues; $19.2M may not sustain operations through expected U.S. launch without additional financing
  • U.S. commercial re-entry depends on successful launch execution and physician adoption of TCAR procedure
  • Voluntary recall of CGuard Prime for CAS remains unresolved; PMA supplement submission and re-launch timeline could slip
  • Company has history of losses and going concern risk; substantial doubt about ability to continue as a going concern

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402158

Track record

29 reports on NSPR

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
  2. Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  3. Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  4. Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  5. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  6. Nov 12, 20264d ago 8-K Bullish 7/10 No price data
  7. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  8. Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  9. Nov 12, 20265d ago Press Release Bullish 7/10 Viewing Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  10. Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026